Aptus Pharma has entered into the Urology therapy segment as part of its ongoing business expansion initiatives. The company will soon be launching a new portfolio of products in this segment, including Silodosin range, Tamsulosin range and Alkalizer formulations.
The introduction of these products is supported by the company’s strong field-sales force and a robust distribution network consisting of 150+ PLS distributors and sub-distributors across India. This new portfolio is expected to contribute significantly to the company’s future revenue growth and profitability.
Aptus Pharma is engaged in the business of marketing, and distribution of finished pharmaceutical formulations. While the company does not own any manufacturing facilities, it operates through a contract manufacturing model.
